13-04-2015
Fototerapia
A interacção da luz com os tecidos biológicos é o ponto de partida para o entendimento da utilização racional da luz em tratamentos médicos. Uma breve revisão das possibilidades existentes leva-nos à terapia fotodinâmica, em particular no tratamento de tumores sólidos. O exemplo do desenvolvimento de um novo fotossensibilizador para terapia fotodinâmica, patenteado pela Universidade de Coimbra e licenciado à empresa Luzitin SA, que está a ser utilizado num ensaio clínico em Portugal, serve de guia para uma apresentação do caminho de uma molécula "from bench to bedside".
CV / Professor Luís Arnaut
Professor at the University of Coimbra, Administrator and CSO of Luzitin SA, Chairman of LaserLeap Technologies SA. Authored >100 scientific papers, 14 books and book chapters, >3200 citations in Google Scholar, 3 patent families that originated ca. 100 national patents, principal investigator (PI) of projects funded in €7 million, including 10 FCT-funded projects, 2 European-funded projects and 5 QREN/PO center projects, and Portuguese PI of 3 European-funded projects. Director of the Coimbra LaserLab, member of the European research infrastructure LaserLab Europe. Director of the FCT PhD Program on Medicinal Chemistry. Distinguished with the Gulbenkian Science Prize (1994), BES Innovation Grand Prize (2008), RedEmprendia/Santander AVCRI Prize (2010), INVENTA Grand Prize for the best Portuguese patent registered between 2001-2010 (2011), and InnoCentive award ID 9933229 (2014). The two patents families licensed to Luzitin SA on a medicinal product protect the first medicine patented by a Portuguese university that reached clinical trials. One patent family licensed to LaserLeap SA, which is at the core of its business. Founder of Luzitin SA and LaserLeap SA, that raised more than 5 M€ in venture capital and non-dilutive funding.
